<DOC>
	<DOCNO>NCT02805842</DOCNO>
	<brief_summary>Aim The primary objective study compare medication adherence medical therapy patient receive once-daily versus twice-daily tacrolimus regimen . Participants 60 adult renal transplant patient randomize 1:2 twice-daily once-daily tacrolimus group Outcomes The primary outcome medication adherence once-daily twice-daily regimen , measure term implementation . Secondary outcome include graft patient survival , renal function adverse event . Follow - 12 month</brief_summary>
	<brief_title>Incidence Non Adherence Treatment With Once-daily Formulation Tacrolimus</brief_title>
	<detailed_description>Following randomization ( Day 0 ) , 60 kidney transplant recipient decease live kidney randomize 1:2 control study- experimental arm . In control arm , name Tacrolimus BID arm , tacrolimus administer unchanged twice daily , morning evening , study -- experimental group name Tacrolimus QD- Advagraf , Advagraf tacrolimus formulation administer daily morning . In group dos adjust maintain tacrolimus trough level 10-12 ng/mL ( day 1-28 ) , 8-10 ng/mL ( day 29-168 ) 6-8 ng/mL thereafter treatment arm . Adjunct immunosuppression . Per-protocol rejection prophylaxis : All patient receive Basiliximab induction 20mg/bw day 0 4 . Methylprednisolone administer intravenous bolus dose 500 mg , 250 mg 125 mg perioperatively , day 0,1 2 . Thereafter oral prednisone give : 20 mg/day ( day 2-14 ) , 15 mg/day ( day 15-30 ) , 10 mg/day ( day 30-45 ) , 7.5 mg/day ( day 45-60 ) 5 mg/day thereafter . MMF ( 2 g BID ) start preoperatively , reduce 500 mg three time daily 14-30 day . Rejection treatment : First-line acute rejection ( AR ) therapy corticosteroid administer dose 500 mg/day 3 day . Mono- and/or polyclonal antibody could use therapy corticosteroid-resistant AR . First-line antibody therapy permit biopsy indicate severe vascular rejection ( Banff IIB III ) . Prophylactic treatment : Prophylactic antiviral treatment oral ganciclovir 450 mg/day , PCP prevention 400 mg Sulfamethoxazole 80 mg Trimethoprim/day give patient day 1-90 . Endpoints . The primary endpoint : • adherence Tacrolimus administration define self-reported number miss drug ingestion score Morisky Medical Adherence Assessment questionnaire Secondary endpoint : • efficacy failure define biopsy proven rejection , renal function , incidence adverse event ( AEs ) graft loss death end analysis period Statistical analysis The data collect analyzed Fisher 's exact test , Wilcoxon ' match pair test Kaplan-Meier 's test</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion Criteria Age : 18 Years 60 Years Gender : Patients willing able participate study Patients sign informed consent form Patients visit center base study schedule protocol Exclusion Criteria Patients previously receive kidney another organ Patients , positive lymphocyte crossmatch Patients PRA &gt; 50 % Patients , underwent desensitization Patients , diagnose cancer last five year Patients , donor positive HIV , HBsAg , antiHCV test result Patients , treat investigated drug within 30 day study enrollment Patients , plan pregnant , pregnant breastfeed planning use contraceptive method study period . Patients addict drugs/alcohol within six month study enrollment Patients , mental illness make appropriate communication impossible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>non adherence</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Advagraf</keyword>
</DOC>